Welcome to
Sanofi in Canada
Toggle navigation
About Us
Science & Innovation
Products and Resources
Patient Support
Our Responsibility
Careers
Media
Toggle navigation
News Releases
Subscribe
Media Contacts
Social Media
News
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Subscribe
Year
All Years
2023
2022
2021
2020
2019
2018
2017
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Photos
Video
Audio
Documents
Events
Standard
May 25, 2021
DUPIXENT® (dupilumab injection) now publicly reimbursed in Ontario and New Brunswick for the treatment of moderate-to-severe atopic dermatitis
Mar 31, 2021
Sanofi to build new manufacturing facility in Toronto to strengthen domestic pandemic preparedness and increase global supply of high-dose influenza vaccine
Mar 22, 2021
Sanofi Canada earns Gold-level gender parity certification for the second straight year
Feb 23, 2021
Health Canada approves DUPIXENT® (dupilumab injection) as the first biologic for the treatment of moderate-to-severe atopic dermatitis in children aged 6 to 11 years
Jan 28, 2021
Sanofi Canada launches Biogenius Grant for high schools, strengthening commitment to equity in the field of STEM learning
Jan 26, 2021
Sanofi Canada named to Forbes Canada's Best Employers list for 2021
Dec 18, 2020
Health Canada approves expanded indication for SOLIQUA®
Dec 8, 2020
Canadians living with multiple sclerosis find support during COVID-19 pandemic through dedicated social media network
Nov 17, 2020
DUPIXENT® (dupilumab injection) now approved by Health Canada for patients with severe asthma
Sep 22, 2020
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
7
8
9
»
